| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma
|
Laganà, Marta
|
|
|
208 |
C |
p.
|
artikel
|
| 2 |
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
|
Bongiovanni, Alberto
|
|
|
208 |
C |
p.
|
artikel
|
| 3 |
Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma
|
van Duin, Isabella A.J.
|
|
|
208 |
C |
p.
|
artikel
|
| 4 |
Beneath the surface: Novel insights into Amivantamab-induced acneiform rash
|
Nikolaou, Vasiliki
|
|
|
208 |
C |
p.
|
artikel
|
| 5 |
Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer
|
Felip, Enriqueta
|
|
|
208 |
C |
p.
|
artikel
|
| 6 |
Corrigendum to “Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study” [Eur. J. Cancer, vol. 205 (2024) 114119]
|
Noujaim, Jonathan
|
|
|
208 |
C |
p.
|
artikel
|
| 7 |
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
|
Rimini, Margherita
|
|
|
208 |
C |
p.
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
208 |
C |
p.
|
artikel
|
| 9 |
Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers
|
Botta, Laura
|
|
|
208 |
C |
p.
|
artikel
|
| 10 |
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients.
|
Orsi, Giulia
|
|
|
208 |
C |
p.
|
artikel
|
| 11 |
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort
|
Anota, Amélie
|
|
|
208 |
C |
p.
|
artikel
|
| 12 |
Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials
|
Choderlos de Laclos, Xavier
|
|
|
208 |
C |
p.
|
artikel
|
| 13 |
Letter re: N0 neck trial: Does intensification of follow-up (Ultrasound + Physical Examination) influence outcomes in early-stage oral cancer?
|
Ram, Bhargav
|
|
|
208 |
C |
p.
|
artikel
|
| 14 |
Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study
|
Jeong, Hyehyun
|
|
|
208 |
C |
p.
|
artikel
|
| 15 |
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
|
Blay, Jean-Yves
|
|
|
208 |
C |
p.
|
artikel
|
| 16 |
Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012–2021)
|
de Nijs, Koen
|
|
|
208 |
C |
p.
|
artikel
|
| 17 |
Oral ADAGRASIB associated with cetuximab unblocks obstructed colorectal cancer
|
Mercier, Léa
|
|
|
208 |
C |
p.
|
artikel
|
| 18 |
Placebo immune-related adverse events (irAEs): A neglected phenomenon in cancer immunotherapy trials
|
Zhou, Yixin
|
|
|
208 |
C |
p.
|
artikel
|
| 19 |
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART
|
Geoerger, Birgit
|
|
|
208 |
C |
p.
|
artikel
|
| 20 |
Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer
|
Park, Siyeon
|
|
|
208 |
C |
p.
|
artikel
|
| 21 |
Response to letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis
|
Martins-Branco, Diogo
|
|
|
208 |
C |
p.
|
artikel
|
| 22 |
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
|
Jansen, Philipp
|
|
|
208 |
C |
p.
|
artikel
|
| 23 |
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
|
Hochmair, Maximilian J.
|
|
|
208 |
C |
p.
|
artikel
|
| 24 |
Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months
|
Franken, Ingrid A.
|
|
|
208 |
C |
p.
|
artikel
|
| 25 |
“Symptomatic” melanoma brain metastases: A call for clear definitions and adoption of standardized tools
|
Le Rhun, Emilie
|
|
|
208 |
C |
p.
|
artikel
|
| 26 |
The survival disparity between children and adolescents and young adults (AYAs) with Ewing sarcoma in the Netherlands did not change since the 1990s despite improved survival: A population-based study
|
Schulpen, Maya
|
|
|
208 |
C |
p.
|
artikel
|
| 27 |
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy
|
Vulsteke, Christof
|
|
|
208 |
C |
p.
|
artikel
|
| 28 |
Whole exome sequencing reveals diverse genomic relatedness between paired concurrent endometrial and ovarian carcinomas
|
Southworth, Emily
|
|
|
208 |
C |
p.
|
artikel
|
Tijdschrift beschrijving